RecruitingPhase 1Phase 2NCT07596901

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis

Sponsor

Aurinia Pharmaceuticals Inc.

Enrollment

81 participants

Start Date

Apr 22, 2026

Study Type

INTERVENTIONAL

Conditions

Myasthenia Gravis, Generalized

Summary

This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aritinercept and Placebo for people with myasthenia gravis, generalized. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.